Oral rivaroxaban for symptomatic venous thromboembolism.

By G. Landman, R. Gans. New England Journal of Medicine, 2011

1,683 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Internal Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/b3b4c26933eb8b38019cb837e9667323a0f1a18b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. S. Schulman
2. G. Agnelli
3. Jeroen J. Bax
4. P. Lancellotti

In Internal Medicine

1. Samuel Z. Goldhaber
2. G. Agnelli
3. S. Konstantinides
4. H. Büller

Citations in the corpus

• Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. (2012, background): “Evaluations of Extended Anticoagulant Therapy Since AT9: When AT9 was written, extended treatment of VTE with VKA therapy had been evaluated in six studies (mostly patients with unprovoked proximal DVT or PE(46,61-64) or a second episode of VTE(65)), and with an NOAC (rivaroxaban vs placebo) in one ”
• [2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism]. (2014, positive): “For example, in the International Cooperative Pulmonary Embolism Registry (ICOPER), age .70 years, systolic BP ,90 mm Hg, respiratory rate .20 breaths/min, cancer, chronic heart failure and chronic obstructive pulmonary disease (COPD), were all identified as prognostic factors.48 In the Registro Inf”
• Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis (2014, background): “(2), intraarticular (1), and other (3), and the sites in the warfarin group were gastrointestinal (10”
• Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). (2018, neutral): “9 Currently receiving cancer treatment§ 142 (70) 140 (69) Chemotherapy 120 (85) 113 (81) Radiotherapy 10 (7) 6 (4) Targeted therapy 22 (15) 21 (15) Endocrine therapy 15 (11) 15 (11) Primary tumor type Bladder 4 (2) 10 (5) Brain 2 (1) 1 (1) Breast 20 (10) 20 (10) Cancer unknown primary 3 (2) 3 (1) Ch”